An ADC designed to target drug-resistant melanomas expressing the receptor tyrosine kinase AXL conjugated to MMAE (AXL-107-MMAE, Genmab) showed cooperative inhibition of melanoma growth when combined with BRAF/MEK inhibitors [18], highlighting the importance of targeting tumor vulnerabilities when designing ADCs. Here, BRAF is linked to melanoma.